Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital

Key Points

• Chardan Capital has reiterated a "Buy" rating for Coya Therapeutics (NASDAQ:COYA) with a price target of $14.00, indicating a potential upside of 146.91% from its current price.
• Other analysts have varied opinions on the stock, with HC Wainwright and D. Boral Capital maintaining a "Buy" rating with price targets of $18.00, while Wall Street Zen downgraded it to "Sell".
• Coya Therapeutics reported a loss of ($0.36) EPS for the last quarter, missing analyst expectations, with projected earnings of -1.15 EPS for the current fiscal year.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by analysts at Chardan Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $14.00 target price on the stock. Chardan Capital's price objective would indicate a potential upside of 154.55% from the company's current price.

COYA has been the topic of several other research reports. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, August 25th. D. Boral Capital restated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Wednesday. Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Lake Street Capital initiated coverage on Coya Therapeutics in a report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $16.50.

Coya Therapeutics Price Performance

Shares of COYA stock traded down $0.24 on Wednesday, hitting $5.50. The stock had a trading volume of 65,309 shares, compared to its average volume of 114,848. The firm has a market capitalization of $91.99 million, a P/E ratio of -4.44 and a beta of 0.26. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $10.24. The company's 50 day moving average price is $6.19 and its 200-day moving average price is $6.03.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The company had revenue of $0.16 million during the quarter, compared to analysts' expectations of $0.78 million. On average, equities analysts forecast that Coya Therapeutics will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several hedge funds have recently bought and sold shares of the company. Northern Trust Corp increased its stake in Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after purchasing an additional 3,099 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new position in Coya Therapeutics in the 1st quarter valued at approximately $65,000. Jane Street Group LLC purchased a new position in Coya Therapeutics in the 4th quarter valued at approximately $74,000. Northwestern Mutual Wealth Management Co. purchased a new position in Coya Therapeutics in the 2nd quarter valued at approximately $119,000. Finally, CM Management LLC increased its stake in Coya Therapeutics by 25.0% in the 1st quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after purchasing an additional 40,000 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.